Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 02, 2024, titled "Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg". | Download
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 02, 2024, titled "Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg". | Download
Final • Div/Share: ₹ 3
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant